Reading VTR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VTR free→Reading VTR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VTR free→NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. Earnings quality is robust, indicating that cash backs up reported profits. The sector backdrop is a headwind, and risk is moderate. Peer multiples imply a price about 51% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified, as it is rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. The analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $84.60. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $85 VTR trades at 6× p/s, below its 8× p/s peer median. Our $64 fair value sits above the price; low confidence. Analysts: $90–$110. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 32% near-term growth, in line with our forecast of about 22%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Real Estate names rated neutral grew net income 53% of the time over the next year (vs 57% for the rest of the cohort, n=1968).
Over the trailing year it converted 6.32x of net income into operating cash flow. Historically, Real Estate names rated robust grew net income 59% of the time over the next year (vs 50% for the rest of the cohort, n=1399).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
2 material management or governance events in the past 24 months, led by executive changes. Historically, Real Estate names rated neutral grew net income 57% of the time over the next year (vs 55% for the rest of the cohort, n=5004).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.17 → $0.11 (-33.3% / 30d). 0 raised, 2 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 81% of analysts rate Buy.
3 PT revisions / 30d. Avg target 14.6% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$65.
How much price usually moves either way.
On a bad day, this stock has moved -$195.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,252.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings affect investor trust and future plans.
Confirms:Net Income per share is above $0.60.
Disproves:Net Income per share is below $0.56.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for VTR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On May 15, 2026, the Company entered into Amendment No. 3 (“Amendment No. 3”) to the ATM Sales Agreement, dated September 18, 2024 (the “Original Agreement”), as amended by that Amendment No. 1 to the ATM Sales Agreement, dated June 13, 2025 (“Amendment No. 1”) and by that Amendment No. 2 to the ATM Sales Agreement dated February 9, 2026 (“Amendment No. 2” and together with Amendment No. 1, Amendment No. 3 and the Original Agreement, the “Sales Agreement”), with BofA Securities,…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$90.00 – $110.00 (median $96.50) · 10 analysts · as of 2026-05-22
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care REITs.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
VTR Ventas | Typical Show detailsSector percentile: 31 of 100 | expensive | moderate |
WELL Welltower | Typical Show detailsSector percentile: 58 of 100 | expensive | low |
OHI Omega Healthcare Investors | Typical Show detailsSector percentile: 63 of 100 | expensive | moderate |
DOC Healthpeak Properties | Above typical Show detailsSector percentile: 72 of 100 | fair | moderate |
AHR American Healthcare REIT | Typical Show detailsSector percentile: 37 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-12.
via XLRE
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Ventas aims to increase its 2026 investment volume expectations to $3 billion, focusing on senior housing.
Ventas focuses on driving growth in SHOP Same-Store Cash NOI through operational improvements.
Ventas aims to enhance its financial flexibility and liquidity to support growth initiatives.
Why it matters: This growth rate is key to understanding the health of Ventas's senior housing segment.
Confirms:Q2 Same-Store Cash NOI growth below 10% year over year.
Disproves:Q2 Same-Store Cash NOI growth of 10% or more year over year.
Why it matters: Changes in liquidity can affect Ventas's ability to grow and pay off debt.
Confirms one read:Liquidity goes up to over $6 billion after taking on debt.
Confirms the other:Liquidity drops below $5 billion after taking on debt.
Why it matters: If this happens, it shows strong demand for senior housing investments. It also shows growth potential.
Confirms:Total investment volume for 2026 is above $3 billion.
Disproves:Total investment volume for 2026 is below $2.5 billion.
Why it matters: Higher interest rates may affect Ventas's money and growth.
Confirms one read:Full year guidance stays stable even with rising interest rates.
Confirms the other:Full year guidance is lowered due to rising interest rates.
Why it matters: Hitting this investment target shows Ventas's commitment to growth in senior housing.
Confirms:$3 billion in senior housing investments will be done by year-end.
Disproves:Investment volume falls short of $2.5 billion by year-end.
Executive Vice President, Outpatient Medical & Research and President and CEO, Lillibridge Healthcare Services, Inc. — Peter J. Bulgarelli: Mr. Bulgarelli retired and entered into a separation agreement with the company.
by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” with the U.S. Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific referenc…